Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 12/01/2026 pm IST			5-day change	1st Jan Change
2,162.00 ^DKK	-0.92%		+7.56%	+6.66%

08/01	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW
08/01	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI

Transcript : Genmab A/S, Q1 2025 Earnings Call, May 08, 2025

Published on 05/08/2025 at 01:10 pm IST - Modified on 06/17/2025 at 10:36 pm IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and welcome to the Genmab's Financial Results Conference Call for the First Quarter of 2025. As a reminder, this conference call is being

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Genmab A/S

08/01	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW
08/01	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI
07/01	Genmab partners with Anthropic to accelerate research and development through agentic AI	RE
07/01	Genmab to Advance R&D Processes via AI Under New Anthropic Partnership	MT
07/01	Genmab, Anthropic to Use AI Tools in Clinical Development	MT
07/01	Genmab partners with Anthropic to accelerate R&D via agentic AI	RE
30/12	Genmab Faces 'Transformative' Year Ahead With Pivotal Trial Readouts, Truist Securities Says	MT
30/12	Genmab Kept at Buy as Truist Securities Forecasts 'Transformative' Year Ahead	MT
30/12	DNB Carnegie Trims Genmab PT, Maintains Hold Rating	MT
30/12	U.S. Futures, European Stocks Mixed	DJ
30/12	SHB: Genmab's Decision to Halt Acasunlimab Development Deemed Logical	FW
30/12	Denmark's Genmab Pulls Plug on Acasunlimab to Prioritize Late-stage Clinical Assets	MT
30/12	DNB Carnegie Lowers Price Target for Genmab to 1,985 Danish Kroner (from 2,050), Reiterates Hold	FW
30/12	Genmab to Cease Clinical Development of Acasunlimab Antibody	MT
29/12	Sector Update: Health Care Stocks Mixed Premarket Monday	MT
29/12	Genmab scraps development of experimental cancer therapy	RE
29/12	Genmab Discontinues Development of Tumor Treatment Acasunlimab	MT
29/12	Genmab Halts Development of Acasunlimab	FW
29/12	Genmab A/S Reaffirms Earnings Guidance for the Year 2025	CI
29/12	Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio Review	CI
19/12	Deutsche Bank Raises Target Price for Genmab to 2,400 Danish Kroner (2,000), Reiterates Buy	FW
12/12	Genmab Finalizes Tender Offer for Dutch Biotech Merus	MT
12/12	Genmab Completes Acquisition of Merus – Bolsters Portfolio with New Cancer Treatment	FW
12/12	Genmab: Completion of Tender Offer for Outstanding Common Shares of Merus N.V.	RE
11/12	Genmab A/S - Special Call